Gaofeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gaofeng Wang has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Luis A. Garza
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
9 shared publications Yue Li
8 shared publicationsZhiqi Hu
Department of Plastic and Aesthetic Surgery Nanfang Hospital, Southern Medical University Guangzhou Guangdong Province China
8 shared publicationsZhen Lin
7 shared publicationsLan Yang
6 shared publicationsLu Chen
6 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (10)
Skin commensals shape the clock-ferroptosis axis to preserve barrier function in psoriasis
- 17 September 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (10)
Open AccessSkin commensals shape the clock-ferroptosis axis to preserve barrier function in psoriasis
- Open Access
IOBRpy enables agentic multi-omics decoding of anti-tumor immunity
Decoding the tumor immunity is pivotal for cancer immunotherapy, yet transcriptomic pipelines remain bottlenecked by fragmented tools and biased interpretations. Here we present IOBRpy, a Python toolkit driven by an innovative AI dual-agent layer for automated, highly standardized immuno-oncology workflows. Moving beyond conventional expression profiling, IOBRpy enables agentic multi-omics decoding. From raw FASTQ or TPM matrices, it seamlessly integrates upstream quality control, transcript quantification, and downstream TME parsing, encompassing signature scoring, ligand-receptor crosstalk, and cellular deconvolution. Crucially, IOBRpy expands data dimensions by incorporating complementary immunogenomic layers, empowering concurrent high-resolution SpecHLA typing and TRUST4-based TCR/BCR repertoire reconstruction from sequencing data. Deployed across two large-scale cohorts (IMvigor210 and OAKPOPLAR), IOBRpy successfully captured multi-dimensional prognostic insights. While broad HLA-I heterozygosity showed negligible impact, it precisely unmasked treatment-stratified, allele-specific survival associations (e.g., HLA-A*01 and HLA-DPA1*02) tightly coupled with distinct immunosuppressive ligand-receptor networks (such as HMGB1-THBD and EFNB2-EPHB6) and dynamic TCR clonal diversity shifts. Empowering this lifecycle is a paired agent framework: a workflow agent automatically audits project states to execute validated, path-aware commands, while a result agent evaluates tool provenance, handles method-aware adaptive visualizations, and organizes findings into evidence-constrained biological hypotheses. Collectively, IOBRpy provides a reproducible, scalable, and intelligence-augmented Python gateway to transform raw sequencing data into multi-omic, interpretation-ready discoveries for cohort-scale precision immunotherapy ( https://iobr.github.io/IOBRpy/ ).
Open AccessIOBRpy enables agentic multi-omics decoding of anti-tumor immunity
Decoding the tumor immunity is pivotal for cancer immunotherapy, yet transcriptomic pipelines remain bottlenecked by fragmented tools and biased interpretations. Here we present IOBRpy, a Python toolkit driven by an innovative AI dual-agent layer for automated, highly standardized immuno-oncology workflows. Moving beyond conventional expression profiling, IOBRpy enables agentic multi-omics decoding. From raw FASTQ or TPM matrices, it seamlessly integrates upstream quality control, transcript quantification, and downstream TME parsing, encompassing signature scoring, ligand-receptor crosstalk, and cellular deconvolution. Crucially, IOBRpy expands data dimensions by incorporating complementary immunogenomic layers, empowering concurrent high-resolution SpecHLA typing and TRUST4-based TCR/BCR repertoire reconstruction from sequencing data. Deployed across two large-scale cohorts (IMvigor210 and OAKPOPLAR), IOBRpy successfully captured multi-dimensional prognostic insights. While broad HLA-I heterozygosity showed negligible impact, it precisely unmasked treatment-stratified, allele-specific survival associations (e.g., HLA-A*01 and HLA-DPA1*02) tightly coupled with distinct immunosuppressive ligand-receptor networks (such as HMGB1-THBD and EFNB2-EPHB6) and dynamic TCR clonal diversity shifts. Empowering this lifecycle is a paired agent framework: a workflow agent automatically audits project states to execute validated, path-aware commands, while a result agent evaluates tool provenance, handles method-aware adaptive visualizations, and organizes findings into evidence-constrained biological hypotheses. Collectively, IOBRpy provides a reproducible, scalable, and intelligence-augmented Python gateway to transform raw sequencing data into multi-omic, interpretation-ready discoveries for cohort-scale precision immunotherapy ( https://iobr.github.io/IOBRpy/ ).
- 23 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1024-1034
Microbiota–fibroblast crosstalk represents the missing link in skin barrier dysfunction and fibrosis
Dermal fibroblasts are key cellular components of the skin stroma, primarily responsible for extracellular matrix synthesis and the maintenance of tissue structure and function. Beyond this canonical role, these cells also possess immune regulatory functions, enabling them to sense and integrate microbial cues to orchestrate cutaneous inflammatory responses, wound repair and fibrogenesis. The skin microbiome is a critical regulator of fibroblast homeostasis; its dysbiosis disrupts fibroblast–microbe crosstalk, leading to aberrant fibroblast activation and contributing to the pathogenesis of various dermatological conditions. Clinically, the burden of these disorders is substantial, and current therapeutic strategies targeting fibroblast dysfunction often yield limited efficacy. Fortunately, recent advances in deciphering the pathophysiological mechanisms underlying fibroblast–microbe interactions have highlighted critical molecular regulatory networks, opening new therapeutic avenues. Among these emerging approaches, interventions targeting the microbiota-fibroblast axis – such as probiotics, postbiotics and fibroblast-directed agents – hold considerable promise. Deciphering the nuances of this crosstalk is pivotal for advancing precision and regenerative therapies, with potential implications for cutaneous and systemic fibrotic disorders.
- 23 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1024-1034
Microbiota–fibroblast crosstalk represents the missing link in skin barrier dysfunction and fibrosis
Dermal fibroblasts are key cellular components of the skin stroma, primarily responsible for extracellular matrix synthesis and the maintenance of tissue structure and function. Beyond this canonical role, these cells also possess immune regulatory functions, enabling them to sense and integrate microbial cues to orchestrate cutaneous inflammatory responses, wound repair and fibrogenesis. The skin microbiome is a critical regulator of fibroblast homeostasis; its dysbiosis disrupts fibroblast–microbe crosstalk, leading to aberrant fibroblast activation and contributing to the pathogenesis of various dermatological conditions. Clinically, the burden of these disorders is substantial, and current therapeutic strategies targeting fibroblast dysfunction often yield limited efficacy. Fortunately, recent advances in deciphering the pathophysiological mechanisms underlying fibroblast–microbe interactions have highlighted critical molecular regulatory networks, opening new therapeutic avenues. Among these emerging approaches, interventions targeting the microbiota-fibroblast axis – such as probiotics, postbiotics and fibroblast-directed agents – hold considerable promise. Deciphering the nuances of this crosstalk is pivotal for advancing precision and regenerative therapies, with potential implications for cutaneous and systemic fibrotic disorders.
Phytic Acid Improves the Skin Barrier Function in Murine Models of Atopic Dermatitis Through Skin Microbiota‐Derived Indole‐3‐Propionic Acid
Background: Barrier dysfunction and dysbiosis of the skin microbiota are two of the key factors in the pathogenesis of atopic dermatitis (AD). Phytic acid (PA) is a common constituent of high‐fiber foods, whereas its role in AD remains unelucidated. The aim of this study was to investigate the effects of PA‐altered skin microbial metabolites on AD and to explore its specific mechanism. Methods: MC903‐induced AD mouse models were used to explore the role of PA on AD by TEWL, immunofluorescence, and qPCR analysis. Using cohouse experiments with feces removal to verify the role of skin microbiota. The specific mechanism of effect of PA was explored through 16S, RNA‐seq, LC–MS/MS, luciferase assay, and in vivo experiments with siRNA. Results: Diet‐derived PA significantly improved the barrier function of MC903‐induced AD, whether administered by gavage or topically. Topical application of PA reshaped the skin microbiota in AD mice and increased tryptophan‐metabolizing bacteria, especially Staphylococcus epidermidis . Furthermore, PA upregulated skin microbiota‐derived indole derivatives, especially indole‐3‐propionic acid (IPA), thus activating AHR to promote the transcription of KRT10, which further ameliorated AD . Conclusion: Our findings showed that diet‐derived PA improved barrier function in AD via altering skin microbiota‐derived metabolites, highlighting PA as a novel therapeutic strategy for the treatment of AD.
Phytic Acid Improves the Skin Barrier Function in Murine Models of Atopic Dermatitis Through Skin Microbiota‐Derived Indole‐3‐Propionic Acid
Background: Barrier dysfunction and dysbiosis of the skin microbiota are two of the key factors in the pathogenesis of atopic dermatitis (AD). Phytic acid (PA) is a common constituent of high‐fiber foods, whereas its role in AD remains unelucidated. The aim of this study was to investigate the effects of PA‐altered skin microbial metabolites on AD and to explore its specific mechanism. Methods: MC903‐induced AD mouse models were used to explore the role of PA on AD by TEWL, immunofluorescence, and qPCR analysis. Using cohouse experiments with feces removal to verify the role of skin microbiota. The specific mechanism of effect of PA was explored through 16S, RNA‐seq, LC–MS/MS, luciferase assay, and in vivo experiments with siRNA. Results: Diet‐derived PA significantly improved the barrier function of MC903‐induced AD, whether administered by gavage or topically. Topical application of PA reshaped the skin microbiota in AD mice and increased tryptophan‐metabolizing bacteria, especially Staphylococcus epidermidis . Furthermore, PA upregulated skin microbiota‐derived indole derivatives, especially indole‐3‐propionic acid (IPA), thus activating AHR to promote the transcription of KRT10, which further ameliorated AD . Conclusion: Our findings showed that diet‐derived PA improved barrier function in AD via altering skin microbiota‐derived metabolites, highlighting PA as a novel therapeutic strategy for the treatment of AD.
- 2 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 1935-1942.e4
The Role of Skin-Gut-Lung Microbiome in Allergic Diseases
- 2 May 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (8) , 1935-1942.e4
The Role of Skin-Gut-Lung Microbiome in Allergic Diseases
- Top Cited PapersOpen Access
- 26 February 2025
- Vol. 4 (1) , e270
Gut–X axis
Recent advances in understanding the modulatory functions of gut and gut microbiota on human diseases facilitated our focused attention on the contribution of the gut to the pathophysiological alterations of many extraintestinal organs, including the liver, heart, brain, lungs, kidneys, bone, skin, reproductive, and endocrine systems. In this review, we applied the “gut–X axis” concept to describe the linkages between the gut and other organs and discussed the latest findings related to the “gut–X axis,” including the underlying modulatory mechanisms and potential clinical intervention strategies.
- 26 February 2025
- Vol. 4 (1) , e270
Top Cited PapersOpen AccessGut–X axis
Recent advances in understanding the modulatory functions of gut and gut microbiota on human diseases facilitated our focused attention on the contribution of the gut to the pathophysiological alterations of many extraintestinal organs, including the liver, heart, brain, lungs, kidneys, bone, skin, reproductive, and endocrine systems. In this review, we applied the “gut–X axis” concept to describe the linkages between the gut and other organs and discussed the latest findings related to the “gut–X axis,” including the underlying modulatory mechanisms and potential clinical intervention strategies.
- 22 November 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 155 (3) , 880-891.e9
Melatonin treatment increases skin microbiota-derived propionic acid to alleviate atopic dermatitis
- 22 November 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 155 (3) , 880-891.e9
Melatonin treatment increases skin microbiota-derived propionic acid to alleviate atopic dermatitis
- Open Access
- 21 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (22) , e70191
A single‐center clinical trial evaluating topical propranolol for preventing stress‐induced hair loss
There is currently a lack of pathological research on the hair loss caused by stress, and there is no effective treatment available. It has been previously reported that stress can cause sympathetic nerve activation and release of norepinephrine, which binds to beta‐2 adrenergic receptors and causes a series of chemical reactions. Propranolol, as a beta‐2 adrenergic receptors blocker, competitively antagonizes the effects of norepinephrine. We initiated a single‐center clinical trial with a self‐controlled approach to assess the effectiveness of topical applied hydrochloride salt of propranolol solution in preventing stress‐induced hair loss in humans. A total of 20 volunteers were enrolled. 14 out of 20 volunteers experienced a significant reduction in the number of hair loss ( p < .05) after using hydrochloride salt of propranolol solution. No local adverse reactions were found. This study showed hydrochloride salt of propranolol solution may alleviate stress‐induced alopecia to a certain extent, which provides clues for the development of pharmaceutical interventions for the treatment of stress‐induced alopecia.
- 21 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (22) , e70191
Open AccessA single‐center clinical trial evaluating topical propranolol for preventing stress‐induced hair loss
There is currently a lack of pathological research on the hair loss caused by stress, and there is no effective treatment available. It has been previously reported that stress can cause sympathetic nerve activation and release of norepinephrine, which binds to beta‐2 adrenergic receptors and causes a series of chemical reactions. Propranolol, as a beta‐2 adrenergic receptors blocker, competitively antagonizes the effects of norepinephrine. We initiated a single‐center clinical trial with a self‐controlled approach to assess the effectiveness of topical applied hydrochloride salt of propranolol solution in preventing stress‐induced hair loss in humans. A total of 20 volunteers were enrolled. 14 out of 20 volunteers experienced a significant reduction in the number of hair loss ( p < .05) after using hydrochloride salt of propranolol solution. No local adverse reactions were found. This study showed hydrochloride salt of propranolol solution may alleviate stress‐induced alopecia to a certain extent, which provides clues for the development of pharmaceutical interventions for the treatment of stress‐induced alopecia.